Dec 01, 2023
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
Nov 21, 2023
Sana Biotechnology to Present at November and December 2023 Investor Conferences
Nov 17, 2023
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
Nov 09, 2023
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
Nov 08, 2023
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
Nov 02, 2023
Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
Oct 10, 2023
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
Aug 30, 2023
Sana Biotechnology to Present at September 2023 Investor Conferences
Aug 03, 2023
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
Jun 16, 2023
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
Displaying 1 - 10 of 26